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Abstract
Inborn errors of metabolism (IEM) are a large and heterogeneous group of genetic diseases. In most of these conditions, the
presence of variants in specific genes leads to enzyme deficiencies that affect a particular metabolic step. The number of
laboratories dedicated to the study of IEM is very limited worldwide, and its multiplication is urgently required for a more
effective diagnosis. With the scarcity of specialized centers, the diagnosis of affected individuals comes too late or does not happen
at all. Moreover, the biological samples have to travel long distances, compromising its quality and delaying still more the diagnosis.
In this work, we suggest a practical guide for a basic biochemical laboratory to get involved in the study of IEM. This proposal was
based on already described metabolic tests and involves the need of just a few, simple, and affordable instruments that can give an
enormous quantity of information about the possible metabolic defect faced, such as a spectrophotofluorometer and a gas
chromatography/mass spectrometry (GC/MS) instrument. The procedures proposed can be customized and adapted to
particular needs and situations, which make it especially useful for developing countries.
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Introduction
Inborn errors of metabolism (IEM) are a large and heteroge-
neous group of genetic diseases. In most of these conditions,
the presence of variants in specific genes leads to enzyme
deficiencies that affect a particular metabolic step. Depending
on the metabolic error involved, the clinical presentation can be
severe or lethal with neurodegenerative process, skeletal
abnormalities, and/or physiologic dysfunctions.1
The global incidence of each particular IEM is low, but
considered all together they represent more than 1 affected
individual each 1000 births. The occurrence of each disease
can be significantly different in particular regions. Based on
clinical suspicions, the biochemical study of IEM generally
begins with qualitative or quantitative tests involving metabo-
lites related to sugars, organic acids, amino acids, sterols, fatty
acids, complex lipids, porphyirins, pterines, purines and pyri-
midines, and so on. These studies can be definitive or presump-
tive to define a specific IEM, and they are complemented with
enzyme assays and/or molecular genetic testing.2,3
The analytical technology used by sophisticated laboratories
for the diagnosis of IEM mainly includes gas chromatography/
mass spectrometry (GC/MS), tandem mass spectrometry (MS/
MS), amino acid analyzer, high-pressure liquid chromatogra-
phy (HPLC), thin-layer chromatography, electrophoresis, and
specific spectrophotometric or fluorometric enzyme assays.
In the last few years, an important strategy for early identifi-
cation of IEM was initiated with the study of acylcarnitines and
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amino acids in newborn infants. With this simple analysis, made
in dried blood spot (DBS) samples, it is possible to prevent the
death or severe damage in affected babies, allowing immediate
complementary studies to define the diagnosis and begin due
therapy. Year after year, new countries or regions are joining
to this scheme and also new metabolites are added to the screen-
ing.4-6 The incorporation of DBS samples was also extended to
perform diverse biochemical assays, especially focused on the
study of lysosomal storage diseases (LSDs). The use of this type
of samples facilitates its transportation from remote areas to
specialized centers and could be extended to other metabolite
studies, since their effectiveness was truly demonstrated.7-20
Despite these advances, an important deficiency is still
evident. The number of laboratories dedicated to the study
of IEM is very limited worldwide, and more laboratories per-
forming IEM screening and diagnosis are required for a more
efficient detection and therapy of patients. In the absence of
specialized centers, the affected individuals are frequently
undiagnosed, or their identification comes too late. Moreover,
the biological samples have to travel long distances to reach a
suitable laboratory, being exposed to deterioration during
shipment and delaying still more the diagnosis.
Here, we present a practical guide for a basic biochemical
laboratory to become involved in the study of IEM. This pro-
posal was based on already described metabolic tests involving
a few, simple, and affordable instruments that can give an
enormous quantity of information about the possible metabolic
defect faced, such as a spectrophotofluorometer and a GC/MS
system. The next section describes the scope of tests that can be
performed and the possible or definitive IEM involved.
Basic Biochemical Laboratory for IEM Study
Detailed biochemical procedures and its limitations can be
found in the references cited in this section.
Screening Tests
Screening tests can be performed with a reactive strip or simple
qualitative procedures as indicated subsequently. Despite being
less used in the present days, these preliminary tests can be useful
to guide the metabolic study, especially in emergency situations.2,3
Reactive Strips. Different reagent strips are commercially avail-
able for quick and qualitative analysis of several intermediates
in urine, including protein, blood, leukocytes, nitrite, glucose,
ketones (acetoacetic acid), pH, specific gravity, creatinine,
bilirubin, and urobilinogen. Other strips allow the quick deter-
mination of reducing substances (glucose, lactose, fructose,
galactose, pentoses, sulfite, etc). The interpretation of the
results can be made by visual observation.
Qualitative tests. Complementing the reactive strip tests, there are
simple qualitative assays that could bring useful information
about the possible metabolic error present. The interpretation
of the results can be made with simple sight, except
the Ehrlich test and Bratton-Marshall reaction where a spectro-
photometer is required.2,3 The most common tests are as follows:
- Benedict test for reducing substances,
- 2,4-Dinitrophenylhydrazine) for a-keto acids,
- Nitroprusside test for cystine and homocystine,
- Nitrosonaphthol test for tyrosine metabolites,
- Ferric chloride test for PKU, Histidemia, MSUD,
Tyrosinemia, Alkaptonuria, etc,
- Ehrlich test for porphyrins,
- Urine thiosulfate determination for defect of sulfite
metabolism,
- Toluidine blue spot test for glycosaminoglycans
(GAGs),
- Electrophoresis and thin-layer chromatography (TLC)




These studies aim to determine total concentration of
specific metabolites and to measure specific enzyme activ-
ities.2,3,7-18,22-24 Chitotriosidase activity can be used for screen-
ing, as it is increased in plasma and DBS in several LSDs.
Creatinine and protein determinations are generally performed
as parameters to normalize other biochemical assays that refer
its results to creatinine or protein concentrations, such as
organic acids, GAGs, sialic acid, enzyme assays in tissues or
leucocytes, and so on. Creatinine concentration is also an
important parameter for the investigation of defects in the
creatine metabolism. A summary of the most common spectro-
photofluorometric measurements is presented in Table 1.
Gas Chromatography and MS
Organic acid assay (total ion chromatogram, TIC). This is one of the
most informative assays that can be easily performed to inves-
tigate many IEM. Through a simple organic acid profile, it is
possible to identify particular products related to a specific
enzyme deficiency or to visualize “flags” that would help guide
new studies. It is important to note that the organic acid profiles
can be different in clinically sick and asymptomatic patients.
As the number of new pathologies is growing fast, new key
metabolites are being identified. Thus, it is not unusual review-
ing old profiles, even those obtained years before. The organic
acid profile also offers interesting information about enriched
diet, drug intake, bacterial or plastic contamination, and so
on.2,3,25-28 A list of IEM that can be studied by organic assays
is presented in Table 2.
Additional specific organic acid detection by GC and MS (simple ion
monitoring, SIM). The extracted organic acids can also be ana-
lyzed by programming the mass spectrometer to detect only
one or few isolated ions, allowing the identification and
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quantification of metabolites at very low concentrations. The
most important ions checked are usually succinylacetone
(tyrosinemia type 1), orotic acid (urea cycle disorders), guani-
dinoacetoacetate (defects of creatine metabolism), methylma-
lonic acid (methylmalonic acidemia and disorder of cobalamin
metabolism), mevalonic acid (mevalonic aciduria), and acetyl-
N-aspartate (Canavan disease).29-34
Very long-chain fatty acids assay. Saturated and nonsaturated fatty
acids and plasmalogens can be easily methylated and analyzed
by GC/MS. The range of fatty acids to be screened include
acids with medium-, long-, and very long-chain plasmalogens,
along with pristanate and phytanate.2,3 The fatty acid profile
can give important information about possible peroxisomal
disorder as described in Table 2.
Sterol profile assay. Sterols can be separated and identified by
GC-MS (TIC and SIM modes). The range of pathologies studied
is detailed subsequently. Similar to the organic acid profile,
many “unknown metabolites” could be the future markers for
novel enzyme deficiencies identified in the future, in the pre- or
postsqualene steps of cholesterol synthesis.2,3,35,36 A list of IEM
that can be studied by the sterol profile is presented in Table 2.
Minimal Requirements for the Basic IEM
Laboratory
Human Resources
Basically, the laboratory should count with qualified techni-
cians for sample preparation, performance of the assays, and
instrument operation. Inclusion of microtechniques with the
use of multiwheel plate systems and/or microfluid-based
enzyme assays22 is recommended. Autosamplers for GC/MS
or other robotic implements are also helpful. This means an
enormous saving of expensive artificial substrates, buffers,
reading times, and so on. Well-organized laboratories are more
efficient, saving time, human effort, and chemical products.
Table 1. Details of Spectrophotoflurometric Assays and the IEM Studied.
Spectrophotoflurometric Assays IEM
Carbohydrates and glycogen
Total galactose test (P); Total fructose test (P); Galactosemia
Total glycogen test and glycogen structure assay (P)2,3 Hereditary fructose intolerance
Enzyme assays3 Glycogenosis type Ia, II, IV, V, VI, VII, and IX
Galactose-1-phosphate, UDP-galactose-4-epimerase (P); fructose-
bisphosphate aldolase, fructose-1,6-bisphosphatase (P); glucose-6-
phosphatase (P); a-glucosidase (P); 1.4-a-glucan branching enzyme
(P); phosphorylase (P); 6-hosphofructokinase (P); phosphorylase b-
kinase (P)
Pyruvate and ketone bodies
Total Lactate, Pyruvate, and Ketone bodies tests (P)2,3 Pyruvate metabolism defects
Porphyrins
Porphobilinogen test (P)2,3 Porphyrin metabolism defects
Pterins
Dihydropteridine reductase assay (P)2,3 Pterin metabolism defects
Purine
Bratton-Marshall reaction (P)21 Purine metabolism defect
Biotin
Biotinidase enzyme assay (P)2,3 Biotinidase Deficiency
Lysosomal storage diseases (GAGs)
Total urinary glycosaminoglycans (GAGs; P); plasma and urine free and




b-galactosidose (F); b-glucosaminidase A (F); b-glucosaminidase A/ B
(F); Arylsulfatase A (P); Galactocerebrosidase (F); a-galactosidose (F);
b-glucosidase (F); Chitotriosidase (F); a-L-iduronidase (F); Iduro-2-sul-
fatase (F); Heparan-N-sulfatase (F); a-N-acetylglucosaminidase (F);
Acetyl CoA:a-glucosaminide-N-acetyltransferase (F); N-acetylglucosa-
mine-6-sulfate (F); N-acetylgalactosamine-6-sulfate (F); Arylsulatase B
(P); b-glucuronidase (F); a-L-fucosidase (F); a-Mannosidase (F); b-Man-
nosidase (F); a-neuraminidase (F); Lipase (F); Ceramidase (F); a-N-
acetylgalactosaminidase (F)
GM1 gangliosidoses; Mucolipidosis II/ III; B variant Tay-Sachs, B1
variant, Sandhoff disease; Metachromatic leukodystrophy; Multiple
sulfatase Deficiency; Krabbe’s disease; Fabry’s disease; Gaucher’s
disease; Niemann-Pick disease types A/B/C; MPS types I, II, III-A, III-
B, III-C, III-D, IV-A, VI, VII; Fucosidosis; a-Mannosidase;
b-Mannosidase; Sialidosis; Galactosialidosis; Wolman disease.
Cholesterol ester storage disease; Farber disease; Shindler Disease
Abbreviations: F, fluorometric assay; IEM, Inborn errors of metabolism; P, spectrophotometric assay.
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The technicians should be backed by professionals who have
a background in inherited metabolic diseases to evaluate the
results and to take the appropriate actions to confirm positive
cases and direct the patients to quick management and therapy.
For the assessment of laboratory performance, it is very
important to adhere to international schemes of quality control,
such as ERNDIM, CDC, and others.
Installations and Instruments
The laboratory should have an appropriate size (around 100 m2
is recommended), with adequate ventilation and temperature
control. This last point is especially important due to the sen-
sitive instrumentation required. Work benches, hermetic hood
for manipulation of toxic gases, nitrogen and helium tanks, and
a safe system for reagent storage and for discarding dangerous
substances are also necessary.
A spectrophotoflurometer and a GC/MS are the major instru-
ments required for the basic IEM laboratory. It is important to
subscribe to maintenance programs. The first instrument is a
single machine with UV-visible and fluorescence detectors. In
the case that a spectrophotometer is already available, only a
spectrofluorometer needs to be added.
Minor instruments also are required, and these are similar to
the ones available in a basic biochemical laboratory, including
vortex, pH meter, digital balance, water bath, plate incubator,
TLC and electrophoresis systems, and so on.
Final Considerations
Figure 1 shows a flowchart for the biochemical study of IEM.
It is clear that a vast number of IEM can be explored with this
basic laboratory. Evidently, not all IEM will be covered, but
the most important areas will be studied. The relatively low
cost of the major equipment required to run this laboratory
makes them quite affordable, especially when compared to
the high cost of an MS/MS or other sophisticated equipment.
This is essentially important in countries or regions where
there is a lack of specialized centers to perform these studies.
Once the basic laboratory is running, the range of the pathol-
ogies investigated can be expanded, incorporating new equip-
ment, such as an amino acid analyzer, HPLC, MS/MS, and
instruments for molecular genetic tests and for cell culture.
Local or regional incidence of IEM and the availability of
therapies should be considered for such expansion. If the
resources are very limited, a GC/MS instrument should be the
first option because of the large scope of IEM that can be
studied through a simple chromatography profiling of organic
acids, very long chain fatty acids, and sterols.
Finally, we should emphasize that the IEM are “rare dis-
eases” when considered individually, but the entire group has a
Table 2. Details of GC/MS assays and the IEM studied.
GC/MS ASSAYS IEM
Urine organic acid assay Defects of aromatic amino acid metabolism
GC/MS, TIC2,3,25–28 Phenylketonuria, tyrosinemia, hawkinsinuria, alkaptonuria
GC/MS, SIM29–34 Defects of branched chain amino acids metabolism
Maple urine syrup disease, dihydrolipoyl dehydrogenase (E3) deficiency, isovaleric acidemia, 3-methylcrotonyl-
CoA carboxilase deficiency, multiple carboxylase deficiency, 3-methylglutaconic aciduria, 3-OH-3-
methylglutaric aciduria, 3-oxothiolase deficiency, propionic acidemia, methylmalonic acidemia, malonyl-CoA
decarboxylase deficiency
Defects of dibasic amino acids metabolism
Glutaric aciduria type I, 2-Ketoadipic aciduria
Defects of fatty acid oxidation/pyruvate/Krebbs cycle/ mitochondrial respiratory chain
Long-, medium-, and short-chain acyl-coA dehydrogenase deficiency, multiple acyl-CoA dehydrogenase
deficiency
Lactic acidemia (pyruvate carboxylase deficiency, pyruvate dehydrogenase deficiency, multiple carboxylase
deficiency, defects in oxidative phosphorylation), 2-ketoglutarate dehydrogenase deficiency, fumarase
deficiency, Barth syndrome
Other organic acidurias:
5-Oxo-prolinuria, D-2-OH-glutaric aciduria, 4-OH-butiric aciduria, Canavan disease, mevalonic aciduria, n-
glyceric aciduria, glyceroluria, hyperoxaluria, ketosis, Reye’s syndrome, thymine and uracil acidurias. Urea
cycle disorders and defects of creatine metabolism
Plasma very long-chain fatty
acid assay
GC/MS, TIC/SIM2,3
X-ALD, defects of phytanic/pristanic acid metabolism, infantile Refsum disease, RCDP, Zellweger and
Zellweger-like syndromes, dihydroxyacetone phosphate acyltransferase deficiency
Plasma Sterol profile assay
GC/MS, TIC/SIM2,3,35,36
Mevalonate kinase deficiency, CHILD syndrome, CDPX2. Greenberg dysplasia, Smith-Lemli-Opitz syndrome,
lathosterolosis, desmosterolosis, sitosterolemia, CTX.
Abbreviations: CDPX2, X linked dominant Conradi-Hünermann chondrodysplasia; CTX, cerebrotendineos xanthomatosis; GC/MS, gas chromatography/mass
spectrometry system; IEM, inborn errors of metabolism; RCDP, rhizomelic chondrodysplasia punctata; SIM, simple ion chromatogram mode; TIC, total ion
chromatogram mode; X-ALD, X linked adrenoleukodystrphy.
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frequency higher than 1 per 1000 births. Moreover, the number
of patients detected and the definition of new IEM are conti-
nually expanding worldwide.37-40 Many centers dedicated to
the study of IEM are offering regular courses and training to
physicians, biochemists, biologists, and related professionals,
helping to extend the knowledge of these diseases and to
encourage the health authorities and other international insti-
tutions to take appropriate actions to address these diseases.
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